Paper39228490
Therapeutic Gene Editing in Dyslipidemias.
Tamehri Zadeh SS and 1 other. Rev Cardiovasc Med, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic Gene Editing in Dyslipidemias. Papers, record 39228490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39228490
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References92
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32951534 | Inactivation of ApoC3 by CRISPR/Cas9 Protects Against Atherosclerosis in Hamsters. | Circ Res | 2020 | https://conductscience.org/library/papers/32951534 | PubMed |
| 2 | 38385290 | ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization. | Arterioscler Thromb Vasc Biol | 2024 | https://conductscience.org/library/papers/38385290 | PubMed |
| 3 | 34940615 | CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. | Metabolites | 2021 | https://conductscience.org/library/papers/34940615 | PubMed |
| 4 | 27575716 | PCSK9: Regulation and Target for Drug Development for Dyslipidemia. | Annu Rev Pharmacol Toxicol | 2017 | https://conductscience.org/library/papers/27575716 | PubMed |
| 5 | 32097710 | CRISPR system: Discovery, development and off-target detection. | Cell Signal | 2020 | https://conductscience.org/library/papers/32097710 | PubMed |
| 6 | 1386087 | Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. | J Clin Invest | 1992 | https://conductscience.org/library/papers/1386087 | PubMed |
| 7 | 23287722 | RNA-guided human genome engineering via Cas9. | Science | 2013 | https://conductscience.org/library/papers/23287722 | PubMed |
| 8 | 37862440 | Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review. | Expert Rev Pharmacoecon Outcomes Res | 2024 | https://conductscience.org/library/papers/37862440 | PubMed |
| 9 | 30504621 | ANGPTL3 Inhibitors - Their Role in Cardiovascular Disease Through Regulation of Lipid Metabolism. | Circ J | 2019 | https://conductscience.org/library/papers/30504621 | PubMed |
| 10 | 24916110 | Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. | Circ Res | 2014 | https://conductscience.org/library/papers/24916110 | PubMed |
| 11 | 38031331 | First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA. | Eur Heart J Cardiovasc Pharmacother | 2024 | https://conductscience.org/library/papers/38031331 | PubMed |
| 12 | 15017359 | Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. | Curr Opin Lipidol | 2004 | https://conductscience.org/library/papers/15017359 | PubMed |
| 13 | 20447543 | Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. | J Am Coll Cardiol | 2010 | https://conductscience.org/library/papers/20447543 | PubMed |
| 14 | 34183861 | Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning. | Nat Biotechnol | 2021 | https://conductscience.org/library/papers/34183861 | PubMed |
| 15 | 16909389 | Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. | Am J Hum Genet | 2006 | https://conductscience.org/library/papers/16909389 | PubMed |
| 16 | 24365577 | The pharmacogenomics of statins. | Pharmacol Res | 2014 | https://conductscience.org/library/papers/24365577 | PubMed |
| 17 | 33609733 | Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. | Mol Ther | 2021 | https://conductscience.org/library/papers/33609733 | PubMed |
| 18 | 29259529 | Genome Editing: Past, Present, and Future. | Yale J Biol Med | 2017 | https://conductscience.org/library/papers/29259529 | PubMed |
| 19 | 19075393 | Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. | J Clin Invest | 2009 | https://conductscience.org/library/papers/19075393 | PubMed |
| 20 | 27096365 | Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. | Nature | 2016 | https://conductscience.org/library/papers/27096365 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42861404 | Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Genome Editing in Inherited Cardiovascular Diseases: Therapeutic Advances, Emerging Editing Platforms, and Translational Challenges. | Cureus | 2026 | https://conductscience.org/library/papers/42861404 | PubMed |
| 42835632 | Rebuilding a protective allele with ADAR site-directed RNA editing. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42835632 | PubMed |
| 42652126 | Lipoprotein(a) as a Cardiovascular Risk Factor: Clinical Significance and Therapeutic Perspectives. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652126 | PubMed |
| 41304947 | Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41304947 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ANGPTL3 | 27329 | PubTator's text mining | https://conductscience.org/library/genes/27329 | NCBI Gene |
| APOC3 | 345 | PubTator's text mining | https://conductscience.org/library/genes/345 | NCBI Gene |
| LDLR | 3949 | PubTator's text mining | https://conductscience.org/library/genes/3949 | NCBI Gene |
| PCSK9 | 255738 | PubTator's text mining | https://conductscience.org/library/genes/255738 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39228490
GET https://conductscience.org/api/papers/v1/39228490/references?page=2